Newly Diagnosed Multiple Myeloma Algorithm : Episode 4
Maintenance Therapy in Patients with Multiple Myeloma
A medical expert shares her treatment approach for a high-risk multiple myeloma patient, considering transplant eligibility, dose escalations, and maintenance therapy based on induction regimen and patient risk factors.
Video Player is loading.
EP: 1.The Role of Biomarkers in Diagnosing Multiple Myeloma
EP: 2.Tailoring Treatment for Patients with Multiple Myeloma
EP: 3.Monitoring Induction Therapy & MRD in Multiple Myeloma
Now Viewing
EP: 4.Maintenance Therapy in Patients with Multiple Myeloma
EP: 5.Key Takeaways on Optimizing Multiple Myeloma Care
Recent Videos
Frontline Setting of Pancreatic Cancer
Treatment Algorithm for Metastatic Pancreatic Cancer
Role of Radiation in Pancreatic Cancer Treatment
NGS and Germline Testing in Pancreatic Cancer
Overview of Pancreatic Cancer Treatment Approach
Deciding Which RP to Utilize
Making Sense of PARP Inhibitors
Consideration for Other Androgen Receptor Inhibitors
Prostate Cancer in 2025
Sequencing Treatment for Endocrine-Resistant Disease
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
